Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Immunotherapy
•
Renal Cell Carcinoma
•
NCI-CCC Tumor Board Question
•
Duke
•
NCI-CCC GU Tumor Board Question
In a patient with metastatic RCC who discontinued nivolumab after a prolonged response to ipilimumab/nivolumab, would you consider re-starting nivolumab at disease progression?
Related Questions
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?
What are your top takeaways in GU Cancers from ESMO 2024?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
What is your preferred regimen for a patient with clear cell RCC, progression after an IO+IO regimen, with a chronic non-healing wound?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
